Matthew
Farrelly,
PhD.
Leadership Role
![Matthew Farrelly portrait](https://public4.pagefreezer.com:443/content/FDA/18-08-2023T10:34/https://www.fda.gov/files/styles/person_portrait_large/public/Matthew_Farrelly_Portrait_IPage%20copy.png?itok=y9CVjERU)
Dr. Matthew Farrelly was appointed as Director of the Office of Science at the Center for Tobacco Products (CTP) of the U.S. Food and Drug Administration in March 2023. In this position, Dr. Farrelly oversees all aspects of the science related to tobacco products, their use, and the resulting morbidity and mortality that we use in making regulatory decisions to ensure they will have the greatest impact on improving public health.
Dr. Farrelly has worked extensively in the field of tobacco and nicotine science for more than 25 years, and is an internationally recognized expert with proven leadership and organizational management skills. He has led or been involved with numerous scientific endeavors related to tobacco control policies and regulatory approaches, including those related to graphic health warning labels, excise taxes, smoke-free policies, quitlines, state tobacco control programs, retail advertising, and flavored tobacco products. He has also extensively researched the influence of mass reach health campaigns, including FDA’s The Real Cost. Dr. Farrelly also has a dedicated passion and vision for scientific innovation, including use of social media to recruit hard-to-reach populations, address-based sampling, redirected inbound calling, panel surveys, mixed mode data collection, and the capture of biometric data with wearable sensors. He has authored or co-authored over 120 articles in the peer-reviewed scientific literature, which have been cited over 10,000 times.
Dr. Farrelly holds a B.A. in Economics and French from Indiana University, and Ph.D. in Economics from the University of Maryland at College Park.
Additional Resources
- Contact Information
- Matthew Farrelly,
- 1-877-287-1373 (9 a.m. - 4 p.m. Eastern)